Related Experiment Video
Updated: Oct 16, 2025
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
Anna R Schreiber1, Michelle Andress2, Jennifer R Diamond1
1Division of Medical Oncology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Abstract:
Introduction Metastatic triple-negative breast cancer (TNBC) is an aggressive cancer with poor survival that is difficult to treat due to a lack of targeted options. Conventional therapies targeting hormone receptors (HR) and human epidermal growth factor 2 (HER2) are ineffective and often chemotherapy is standard-of-care. Sacituzumab govitecan is an antibody drug conjugate (ADC) comprised of an active metabolite of irinotecan, SN-38, bound to a humanized monoclonal antibody targeting trophoblastic cell-surface antigen 2 (Trop-2). Trop-2 is highly expressed on the surface of TNBC cells, making it an attractive target. Areas covered We explore the mechanism, pharmacology, efficacy, safety, and tolerability of sacituzumab govitecan. A literature search was conducted via PubMed using keywords such as 'sacituzumab govitecan,' and 'metastatic TNBC.' Expert opinion Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial. Common adverse effects were neutropenia, diarrhea, and nausea, however these effects were manageable with supportive care. Sacituzumab govitecan has shown promise in cancers outside of TNBC, such as urothelial and lung and is being evaluated in HR-positive breast cancers. It is likely we will see this therapy used in combination with other novel targeted agents as current clinical trials mature.
Insights
Sacituzumab govitecan offers survival benefits for metastatic triple-negative breast cancer (TNBC) patients. This antibody drug conjugate targets Trop-2, showing manageable side effects and potential in other cancers.
Area of Science:
- Oncology
- Pharmacology
- Medical Therapeutics
Background:
- Metastatic triple-negative breast cancer (TNBC) presents significant treatment challenges due to lack of targeted therapies.
- Conventional treatments like hormone receptor (HR) and HER2-targeted therapies are ineffective for TNBC.
- Chemotherapy remains the standard of care for metastatic TNBC, often with limited success.
Purpose of the Study:
- To review the mechanism of action, pharmacology, efficacy, and safety of sacituzumab govitecan.
- To evaluate sacituzumab govitecan as a targeted therapy for metastatic TNBC.
- To explore the potential of sacituzumab govitecan in other cancer types.
Main Methods:
- Literature search conducted using PubMed.
- Keywords included 'sacituzumab govitecan' and 'metastatic TNBC'.
- Review of data from clinical trials, including the ASCENT trial.
Main Results:
- Sacituzumab govitecan demonstrated promising survival benefits in patients with previously treated metastatic TNBC.
- Common adverse effects included neutropenia, diarrhea, and nausea, which were manageable with supportive care.
- The antibody drug conjugate (ADC) targets Trop-2, which is highly expressed on TNBC cells.
Conclusions:
- Sacituzumab govitecan represents a significant advancement in treating metastatic TNBC.
- The therapy shows potential for use in other cancers, including urothelial and lung cancers.
- Future research may involve combining sacituzumab govitecan with other novel targeted agents.
More Related Videos
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy